{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-046028","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.901746+00:00","generated_at":"2026-05-30T01:35:31.824157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition","bullets":["Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.","Pro forma cash $37M post-merger with Opus Genetics; expects runway into 2026.","Acquisition of Opus Genetics closed Oct 22; issued 5.2M common shares and 14,145 Series A preferred.","Pipeline: four data readouts in 2025 including Phase 3 for Phentolamine in presbyopia and dim light.","Gene therapy candidate OPGx-LCA5 showed visual improvement in 3/3 adult patients; pediatric enrollment Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-046028","json":"https://secwatch.observer/filing/0001140361-24-046028.json","markdown":"https://secwatch.observer/filing/0001140361-24-046028.md","text":"https://secwatch.observer/filing/0001140361-24-046028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/0001140361-24-046028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:35:31.824157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}